Pharyngotonsillitis — the acute inflammation of the pharyngeal mucosa and palatine tonsils caused by viral pathogens in seventy to eighty percent of cases and group A Streptococcus pyogenes in the remainder — represents the single largest driver of inappropriate antibiotic prescribing in outpatient medicine, with the Pharyngotonsillitis Treatment Market reflecting the diagnostic technology revolution that promises to replace empirical antibiotic therapy with pathogen-directed treatment.

Rapid antigen detection tests and their limitations — the decades-long reliance on throat swab rapid strep tests (RADT) with eighty to ninety percent specificity but only seventy to ninety percent sensitivity, creating the clinical dilemma of false-negative results in patients with high Centor/McIsaac scores. The traditional reflex culture for negative RADT adding twenty-four to forty-eight hours of delay and patient anxiety, driving the adoption of nucleic acid amplification tests (NAAT) such as Abbott ID NOW Strep A and Cepheid Xpert Xpress Strep A that deliver PCR-level sensitivity and specificity in under fifteen minutes at the point of care.

Antibiotic stewardship and penicillin preservation — the global antimicrobial resistance crisis making pharyngotonsillitis a priority target for stewardship programs, with penicillin V and amoxicillin remaining first-line therapy for confirmed streptococcal infection due to enduring susceptibility and narrow spectrum. The five to seven day course duration (reduced from ten days in recent guidelines for uncomplicated cases) and the investigation of single-dose intramuscular benzathine penicillin G for compliance-challenged patients, while macrolides and clindamycin reserved for penicillin-allergic patients with confirmed non-type I hypersensitivity.

Tonsillectomy indication refinement — the Paradise criteria (seven episodes in one year, five per year for two years, or three per year for three years) still guiding surgical referral, but with additional consideration of peritonsillar abscess history, antibiotic allergy/intolerance, PFAPA syndrome overlap, and quality-of-life impact. The transition from cold steel dissection to coblation, harmonic scalpel, and intracapsular partial tonsillectomy techniques that reduce postoperative pain and hemorrhage risk, particularly in pediatric patients where recovery time and parental concern drive technique selection.

Do you think widespread point-of-care molecular testing will eliminate empirical antibiotic prescribing for sore throats entirely, or will the cost and infrastructure requirements of NAAT platforms maintain RADTs and clinical scoring as the dominant approach in primary care?

When are antibiotics indicated for pharyngotonsillitis, and which agents are preferred? Indications: Confirmed group A streptococcal (GAS) pharyngitis by RADT, culture, or NAAT; clinical suspicion with high Centor/McIsaac score (≥4) pending test results; scarlet fever; history of rheumatic fever or post-streptococcal glomerulonephritis (treat empirically while awaiting confirmation). Not indicated: Viral pharyngitis (majority of cases); mononucleosis (ampicillin/amoxicillin cause rash); most cases of viral tonsillitis. First-line: Penicillin V (phenoxymethylpenicillin) — 250 mg 2-3x daily (children) or 500 mg 2-3x daily (adults) for 5-10 days; amoxicillin 50 mg/kg once daily (max 1g) for 10 days or divided BID — better palatability, especially pediatric; benzathine penicillin G IM single dose (1.2 million units if >27 kg; 600,000 units if <27 kg) — guaranteed compliance. Alternatives: Cephalexin (if non-anaphylactic penicillin allergy); azithromycin (if type I penicillin hypersensitivity — 12 mg/kg day 1, then 6 mg/kg days 2-5); clindamycin (if macrolide resistance concern — 7 mg/kg/dose TID). Duration: 10 days traditional; recent studies support 5-7 days for amoxicillin in uncomplicated cases; single-dose IM for compliance issues.

How do you differentiate viral from bacterial (strep) pharyngotonsillitis clinically? Centor/McIsaac criteria (1 point each): Tonsillar exudates; tender anterior cervical adenopathy; fever >38°C; absence of cough; age 3-14 years (+1), 15-44 years (0), >45 years (-1). Interpretation: 0-1 point — low risk (<10% GAS), no testing or antibiotics; 2-3 points — intermediate (15-30%), perform RADT/NAAT, treat if positive; ≥4 points — high risk (>40%), test and treat if positive or empirically treat while awaiting culture. Clinical features favoring GAS: Sudden onset; severe sore throat; fever >38.3°C; tonsillar exudates; tender anterior cervical nodes; headache; abdominal pain (children); palatal petechiae; scarlatiniform rash. Features favoring viral: Gradual onset; cough; coryza; conjunctivitis; hoarseness; diarrhea; oral ulcers; viral exanthem. Mononucleosis clues: Fatigue, posterior cervical adenopathy, splenomegaly, prolonged course; atypical lymphocytes on smear; heterophile antibody or EBV VCA-IgM positive.

What are the indications for tonsillectomy in recurrent pharyngotonsillitis? Paradise criteria (absolute): ≥7 episodes in past year; OR ≥5 episodes per year for 2 consecutive years; OR ≥3 episodes per year for 3 consecutive years; AND each episode documented by physician examination or GAS test. Modified/indications: Tonsillar hypertrophy causing obstructive sleep apnea; peritonsillar abscess (controversial — some advocate interval tonsillectomy after 1-2 episodes); failed antibiotic therapy (multiple allergies/intolerances); PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis); quality of life impact (missed school/work, significant morbidity); suspicion of malignancy (asymmetric tonsillar enlargement, persistent unilateral mass). Surgical techniques: Cold steel dissection and snare (gold standard, lowest primary hemorrhage); electrocautery/dissection (common, increased thermal injury); harmonic scalpel (ultrasonic vibration, less thermal damage than electrocautery); coblation (controlled ablation, less post-op pain in some studies); intracapsular/partial tonsillectomy (preserves capsule, lower hemorrhage risk, possible regrowth). Risks: Primary hemorrhage (0.5-2%, usually within 24 hours); secondary hemorrhage (5-10 days, sloughing of eschar); dehydration (pediatric); velopharyngeal insufficiency (rare); taste disturbance (glossopharyngeal nerve injury, rare).

#Pharyngotonsillitis #StrepThroat #AntibioticStewardship #Tonsillectomy #PointOfCareTesting #ENT